Dinardo CD, Erba HP, Freeman SD, et al. Acute myeloid leukaemia. Lancet (London, England). 2023;401(10393):2073–86.

Article  CAS  PubMed  Google Scholar 

Lichtenegger FS, Krupka C, Haubner S, et al. Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol. 2017;10(1):142.

Article  PubMed  PubMed Central  Google Scholar 

Thol F, Heuser M. Treatment for relapsed/refractory acute myeloid leukemia. HemaSphere. 2021;5(6):e572.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang F, Mao Y, Lu B, et al. A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia. Sci Rep. 2021;11(1):14657.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng Y, Tao Y, Zhang Y, et al. CD25: a potential tumor therapeutic target. Int J Cancer. 2023;152(7):1290–303.

Article  CAS  PubMed  Google Scholar 

Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125(9):1470–81.

Article  CAS  PubMed  Google Scholar 

Han Y, Dong Y, Yang Q, et al. Acute myeloid leukemia cells express ICOS ligand to promote the expansion of regulatory T cells. Front Immunol. 2018;9:2227.

Article  PubMed  PubMed Central  Google Scholar 

Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113(8):619–27.

Article  CAS  PubMed  Google Scholar 

Moon Y, Kim Y, Kim M, et al. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. Ann Clin Lab Sci. 2004;34(4):410–5.

CAS  PubMed  Google Scholar 

Damoiseaux J. The IL-2 - IL-2 receptor pathway in health and disease: the role of the soluble IL-2 receptor. Clin Immunol (Orlando, Fla). 2020;218:108515.

Article  CAS  Google Scholar 

Bakhtiyari M, Liaghat M, Aziziyan F, et al. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. Cell Commun Signal. 2023;21(1):252.

Article  PubMed  PubMed Central  Google Scholar 

Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237–53.

Article  CAS  PubMed  Google Scholar 

Mahabala C, Koushik VK, Manjrekar PA, et al. Serum soluble interleukin-2 receptor (sIL-2R) is an accurate biomarker for dengue-associated hemophagocytic lymphohistiocytosis syndrome diagnosed by Hscore. Infection. 2023;51(2):433–8.

Article  CAS  PubMed  Google Scholar 

Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.

Article  PubMed  Google Scholar 

Sise ME, Wang Q, Seethapathy H, et al. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. J Immunother Cancer. 2023;11(1).

Akiyama M, Sasaki T, Kaneko Y, et al. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren’s syndrome adults from a defined population. Clin Exp Rheumatol. 2018;36(Suppl112):157–64.

PubMed  Google Scholar 

Jülich M, Kanne AM, Sehnert B, et al. Serological lymphocytic activity and patient-reported outcomes in Sjögren’s syndrome. Clin Rheumatol. 2018;37(9):2361–6.

Article  PubMed  Google Scholar 

Werner MCF, Wirgenes KV, Shadrin AA, et al. Limited association between infections, autoimmune disease and genetic risk and immune activation in severe mental disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2022;116:110511.

Article  CAS  PubMed  Google Scholar 

He L, Shu X, Liu X, et al. Soluble IL-2 receptor in dermatomyositis: its associations with skin ulcers and disease activity. Mediat Inflamm. 2020;2020:6243019.

Article  Google Scholar 

Chan CH, Lai CK, Leung JC, et al. Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy. Eur Respir J. 1995;8(1):70–3.

Article  CAS  PubMed  Google Scholar 

Saghazadeh A, Rezaei N. Central inflammatory cytokines in tuberculous meningitis: a systematic review and meta-analysis. J Interf Cytokine Res Off J Int Soc Interf Cytokine Res. 2022;42(3):95–107.

Article  CAS  Google Scholar 

Chen W, Zhang Q, Li M, et al. Clinical diagnostic value of serum soluble IL-2 receptor for stage I sarcoidosis in benign isolated mediastinal and hilar lymphadenopathy. Clin Chim Acta Int J Clin Chem. 2023;545:117372.

Article  CAS  Google Scholar 

Yu X, Niu Y, Xu J, et al. The clinical significance of plasma sCD25 as valuable biomarker for progression and prognosis of tuberculosis. BMC Infect Dis. 2024;24(1):115.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eurelings LEM, Miedema JR, Dalm V, et al. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS ONE. 2019;14(10):e0223897.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katsuya H, Shimokawa M, Ishitsuka K, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130(1):39–47.

Article  CAS  PubMed  Google Scholar 

Gupta M, Stenson M, O’Byrne M, et al. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(1):165–72.

Article  CAS  Google Scholar 

Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood. 2011;118(10):2809–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jo SA, Hwang SH, Chang CL, et al. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin’s lymphoma. Korean J Lab Med. 2010;30(6):600–5.

CAS  PubMed  Google Scholar 

Yoshizato T, Nannya Y, Imai Y, et al. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13(4):410–6.

Article  CAS  PubMed  Google Scholar 

Yoshida N, Oda M, Kuroda Y, et al. Clinical significance of sIL-2R levels in B-cell lymphomas. Plos One. 2013;8(11):e78730.

Article  PubMed  PubMed Central  Google Scholar 

Shirouchi Y, Nishimura N, Mishima Y, et al. Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy. Sci Rep. 2023;13(1):13713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bien E, Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomark Biochem Indic Expo Res Susceptibility Chem. 2008;13(1):1–26.

CAS  Google Scholar 

Tozuka T, Yanagitani N, Yoshida H, et al. Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients. Invest New Drugs. 2023;41(3):411–20.

Article  CAS  PubMed